Crizotinib | Tocris Bioscience 4368/50 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Tocris Bioscience

product type :

chemical

product name :

Crizotinib

catalog :

4368/50

quantity :

50 mg

price :

1075 USD

citations: 3

Reference
Ayoub N, Al Shami K, Alqudah M, Mhaidat N. Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents. Onco Targets Ther. 2017;10:4869-4883 pubmed publisher
Sullivan K, Padilla Just N, Henry R, Porter C, Kim J, Tentler J, et al. ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53. Nat Chem Biol. 2012;8:646-54 pubmed publisher
Qi J, MCTIGUE M, Rogers A, Lifshits E, Christensen J, JÃ¤nne P, et al. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res. 2011;71:1081-91 pubmed publisher

product information

CHEMISTRY :

ClC1=[C@@]([C@H](OC2=C(N)N=CC(C3=CN(C4CCNCC4)N=C3)=C2)C)C(Cl)=CC=C1F

Stock Reference :

4368/50

Cat Number :

4368

Product Name :

Crizotinib

Cas Number :

[877399-52-5]

Unit Size :

50 mg

Size :

Unit :

USD :

1075 USD

Primary Category :

Enzyme-Linked Receptors

Secondary Category :

Receptor Tyrosine Kinases (RTKs)

Tertiary Category :

ALK

Primary Action :

Potent c-MET/ALK inhibitor

Biological Description :

Potent inhibitor of c-MET and anaplastic lymphoma kinase (ALK) (cell IC50 values are 8.0 and 20 nM respectively). Selective for c-MET and ALK against >120 different kinases. Displays antitumor efficacy in multiple tumor models; inhibits c-MET-dependent proliferation, migration and invasion of human tumor cells in vitro. Orally bioavailable.

Storage :

Store at +4°C

Formula :

C21H22Cl2FN5O

Molwt :

450.34

Minimum Purity :

> 99%

Solubility :

Soluble to 10 mM in DMSO and to 100 mM in 2eq.HCl

RTECS No :

Not available

Synonyms :

PF 02341066 PF 2341066

Public Caveats :

Sold for research purposes under agreement from Pfizer Inc.